Open AccessPyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
Annals Of Translational MedicinePeer ReviewedFeng Li +62021Journals
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support